Consider small-cap biotech CorMedix (CRMD), which is viewed as undervalued after the market misinterpreted its recent strategic acquisition of Melinta. TG Therapeutics (TGTX) offers a compelling growth opportunity with its MS drug Briumvi, which has market exclusivity until 2042 and targets a potential 10x revenue increase by 2030. A recent 20% price drop in AI-powered beauty company Oddity Tech (ODD) may present a buying opportunity, given its strong recurring revenue model. Look into real estate disruptor The Real Brokerage (REAX), which is rapidly gaining market share in a weak housing market and is positioned for significant growth. Finally, watch Hims & Hers (HIMS) for a catalyst from its expected mid-September launch of testosterone and menopause treatments, though an entry below $40 is suggested due to high volatility.

Hims & Hers Health, Inc. (HIMS)

• Sentiment: The speaker is very bullish and holds this as a long-term position, calling it a "top three channel favorite."
• Recent Catalysts: The narrative around the stock is improving significantly.
  • GLP-1 Lawsuit Risk Fading: The market is beginning to believe that a potential lawsuit from Novo Nordisk regarding compounded GLP-1s is unlikely to happen or will not be significantly harmful to HIMS.
  • New Product Launches: There are rumors of a mid-September launch for testosterone and menopause treatments (Hormone Replacement Therapy or HRT). This shifts the focus from GLP-1s to a potentially massive new market.
• Business Model Strengths:
  • The business has over 90% recurring revenue.
  • It is a cash-pay model, meaning it does not rely on insurance companies.
  • Products are considered "recession-resistant" and "sticky" (e.g., treatments for ED, hair loss, anxiety), as consumers are unlikely to stop using them.
  • The company is well-positioned within major trends like telehealth, delivery services, and AI-driven personalization.
• Valuation & Price Action:
  • The speaker notes the stock is still "very, very cheap" based on his custom metrics.
  • He acknowledges he would not add to his position at current prices after the recent run-up, preferring to buy below $40.
  • The stock is extremely volatile, with the potential for 20-30% moves in a single day. This volatility attracts traders who write options (puts and calls) on the stock.

Takeaways

• The investment thesis for HIMS is strengthening as the perceived risk from GLP-1 lawsuits diminishes and the company pivots towards a major new product category in HRT.
• The core business is strong, with high recurring revenue and essential products, making it resilient.
• Investors should be prepared for high volatility. While the speaker is a long-term bull, he suggests that the best entry points have been during periods of fear and significant price drops.

Tesla, Inc. (TSLA)

• Sentiment: The speaker is extremely bullish on the long-term vision of Tesla. It is his second-largest holding.
• Key Growth Drivers (Beyond Cars):
  • Robo-taxi: The robo-taxi network is rolling out, with the app reportedly becoming #1 in the travel category on the app store.
  • Optimus Robot: The third-generation prototype of the Optimus robot makes the "embodied AI" vision more tangible. The company's mission has officially expanded to include bots.
  • xAI Integration: A potential vote to bring ownership of xAI into Tesla could be a significant catalyst.
  • Energy Business: The speaker believes Tesla is positioned to become the largest utility in America by creating a decentralized energy network using solar panels on homes and vehicle batteries.
• Valuation Perspective:
  • The speaker believes the stock is "way too cheap" if its long-term vision for AI, robotics, and energy is realized.
  • He suggests that top companies could reach $10 to $20 trillion market caps in the 2030s, framing Elon Musk's compensation plan in that future context.
• Mentioned Risks:
  • The stock is subject to frequent and coordinated "FUD attacks" (Fear, Uncertainty, and Doubt) in the media, which can cause sharp, temporary price drops.

Takeaways

• The investment case for TSLA is not just about electric vehicles but about a future dominated by AI, robotics (Optimus), autonomous transportation (Robo-taxi), and decentralized energy.
• The current valuation is seen as low relative to this massive long-term potential.
• Investors need to have a strong conviction and long-term horizon to withstand the volatility caused by negative news cycles.

CorMedix Inc. (CRMD)

• Sentiment: Bullish. The speaker highlights the company as being "so, so, so cheap."
• Core Product: DefendCalf:
  • This is the only FDA-approved product that reduces catheter-related blood infections for dialysis patients by 70%.
  • It is a money-saving solution for the healthcare system. The product costs around $250 per vial, while a single infection can cost the system $80,000 to $100,000. This makes reimbursement from Medicare very secure.
• Recent Acquisition:
  • CRMD recently acquired a company called Melinta, which has a portfolio of anti-infection products.
  • The speaker believes this is a major positive, as it removes the risk of CRMD being a single-product company.
  • The market sold off on the news (as it often does with acquisitions), which the speaker views as a misunderstanding of the deal's strategic value.

Takeaways

• CRMD is presented as a deep value play in the small-cap biotech sector.
• The investment thesis is based on a unique, FDA-approved product that saves the healthcare system money, ensuring its adoption and reimbursement.
• The recent acquisition of Melinta is seen as a key de-risking event that the market has not yet appreciated, potentially creating a buying opportunity.

TG Therapeutics, Inc. (TGTX)

• Sentiment: Very bullish, calling it a "great company."
• Bullish Thesis: A "Rent-Seeking" Play:
  • The company's main product, Briumvi, is a treatment for Multiple Sclerosis (MS).
  • The FDA has decided it will only approve three specific treatments for MS, and Briumvi is the last one. This creates a near-duopoly.
  • The product has a protected runway with market exclusivity until 2042.
• Product Advantages:
  • Briumvi is a newer, more advanced treatment.
  • It takes less time to administer than its main competitor.
  • It does not carry a breast cancer risk on its label, unlike some alternatives.
• Growth Projections:
  • The total market for relapsing MS treatments is projected to be $12 billion by 2030.
  • If TGTX captures just one-third of this market, it would mean $4 billion in annual sales, a potential 10x increase in revenue in roughly four to five years.

Takeaways

• TGTX offers an investment opportunity based on a strong regulatory moat. The FDA's decision provides a long and protected revenue stream until 2042.
• The company's product is viewed as superior to its main competitor, suggesting it can gain significant market share.
• The potential for 10x revenue growth by 2030 makes this a compelling growth story within the biotech space.

The Real Brokerage Inc. (REAX)

• Sentiment: Bullish. The speaker calls it his "new play on real estate."
• Bullish Thesis: A Real Estate Disruptor:
  • REAX is an asset-light, app-based real estate brokerage.
  • It disrupts traditional brokers by attracting top-performing agents with a more favorable commission structure, including stock options and a commission cap.
• Key Strengths:
  • The business model allows agents to be more competitive on their own commission rates, as the brokerage takes a smaller cut.
  • This model has enabled REAX to grow its agent count, transactions, and revenue extremely fast.
• Market Performance:
  • The speaker emphasizes that REAX has achieved this rapid growth during one of the worst real estate markets in recent history, with pending home sales lower than the 2008 crisis.
  • He views the stock as "very cheap" and "under-followed."

Takeaways

• REAX is a high-growth disruptor in the real estate industry. Its ability to thrive in a historically weak market demonstrates the strength of its business model.
• The company is positioned for potentially explosive growth if and when the real estate market recovers.
• It is presented as an under-the-radar opportunity that combines elements of both value and growth.

Oddity Tech Ltd. (ODD)

• Sentiment: Bullish. The speaker prefers it over competitor e.l.f. Beauty (ELF).
• Bullish Thesis: AI-Powered Beauty:
  • ODD is a direct-to-consumer (DTC) beauty company that uses AI to develop new brands and create personalized products, such as foundation perfectly matched to a customer's skin tone.
• Business Model Highlights:
  • The business model shares many strengths with HIMS: it is cash-pay, has highly recurring revenue, and is a "sticky" business because once a customer finds their perfect match, they are likely to keep reordering.
  • The company is driven by social media marketing and is launching a new brand in the dermatology sector soon.
• Valuation & Outlook:
  • The speaker is puzzled by a recent 20%+ drop in the stock price following what he described as "amazing numbers."
  • He considers the stock "so cheap" and sees potential for significant international growth, as the business is currently focused on the U.S.

Takeaways

• ODD is a unique blend of a beauty company and a tech company, using AI as a key competitive advantage.
• The business model is strong, with sticky products and recurring revenue, similar to other successful DTC companies.
• The recent significant drop in the stock price, despite strong performance, could represent an attractive entry point for investors who believe in its AI-driven approach and growth potential.